From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
CAS Number 334476-64-1
ATC code none
PubChem CID 9832383
Chemical data
Formula C23H21F10N3O
Molar mass 545.416 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vestipitant is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It is under development as a potential antiemetic and anxiolytic drug,[1][2] and as a treatment for tinnitus.[3]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. Reddy GK, Gralla RJ, Hesketh PJ. Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Supportive Cancer Therapy. 2006 Apr 1;3(3):140-2. PMID 18632487
  2. Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, de Nanteuil G, deJong TR, Olivier B, Millan MJ. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. European Neuropsychopharmacology. 2008 Oct;18(10):729-50. PMID 18657401
  3. NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss